Loading clinical trials...

Adjuvant Chemotherapy in High Risk Stage II Colon Cancer | Clinical Trials | Clareo Health

UNKNOWNPHASE3

Adjuvant Chemotherapy in High Risk Stage II Colon Cancer

Adjuvant Chemotherapy Versus Observation in Stage II Colon Cancer Patients With High-Risk Factors and High-Immunoscore®

NCT04303429•Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Summary

* Benefit of adjuvant chemotherapy after curative surgery for stage II Colon Cancer is still debated. Several high-risk features may help to stratify stage II cancer patients into groups that will truly benefit from adjuvant chemotherapy. However, those factors are rather subjective, and no specific trial has been designed to answer the high-risk stage II colon cancer question directly. * Immunoscore® Colon, an in vitro diagnostic test, which quantifies the density of CD3+ and CD8+ T lymphocyte populations in the center the tumor (CT) and its invasive margin (IM) using immunohistochemistry and automated image analysis. Immunoscore® has been extensively validated as a prognostic biomarker in early stage CC patients. This unique diagnostic assay measuring host immune response at the tumor site may inform the decision to administer adjuvant chemotherapy in resected Stage II and III CC patients. * This randomized trial is studying how observation compares to adjuvant chemotherapy (investigator's choice) in stage II colon cancer patients with high-risk features and High-Immunoscore®. The trial would represent a unique opportunity to classify stage II CC patients based on their tumor microenvironment with the aim to provide efficient patient stratification to improve clinical care.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age 18-75 years old
•2. Pathologically confirmed adenocarcinoma of the colon
•3. Complete resection of the primary tumor without gross or microscopic evidence of residual disease
•4. Histologically proven stage II: T3-T4 N0
•5. At least one of the following factors:T4 staging,Number of examined lymph nodes \< 12,poor differentiation (except MSI-H),LVI or PNI,tumor perforation or occlusion
•6. Treatment within 7 weeks following surgery
•7. ECOG PS 0-1
•8. No prior chemo, immuno or radiotherapy
•9. Patients must read, agree to, and sign a statement of Informed Consent prior to participation in this study.

Exclusion Criteria

•1. Have a birth plan during the clinical trial;
•2. Severe cardiovascular diseases such as cerebrovascular accidents occurring within 6 months, myocardial infarction, hypertension that cannot be controlled after drug intervention, unstable angina pectoris, heart failure (NYHA 2-4), and arrhythmia requiring drugs Intervention;
•3. Dementia, mental state changes or any mental illness that may interfere with understanding or making informed consent or completing a questionnaire;
•4. Subjects with ≥1 peripheral neuropathy according to CTCAE V version 4.03;
•5. Allergy or hypersensitivity history of the drug or drug ingredient used in this test;
•6. Excluding other malignant tumors, cured basal cell carcinoma of the skin or squamous cell carcinoma of the skin or any other part of the carcinoma in situ;
•7. Have received any other test drug treatment or participated in another interventional clinical trial within 30 days of the screening period;
•8. The investigator believes that it is not suitable for inclusion.

Key Dates

Start Date

August 1, 2020

Primary Completion Date

January 1, 2022

Completion Date

January 1, 2025

Last Updated

April 8, 2020

Enrollment

962

ESTIMATED participants

Conditions

Stage II Colon CancerAdjuvant Chemotherapy

Interventions

FOLFOX/XELOX/Capecitabine

DRUG

Contacts

qi li, MD,PhD

CONTACT

+8613818207333 Leeqi2001@hotmail.com

Haiyan Zhang, MD

CONTACT

+8613611956117 Zhymmx@sina.com

Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer

NCT06155305

OrganoidsBreast Cancer+1 more

View study

RECRUITINGPHASE3

Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC

NCT06714604

Locally Advanced Pancreatic AdenocarcinomaBorderline Resectable Pancreatic Carcinoma+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 8, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Adjuvant Chemotherapy in High Risk Stage II Colon Cancer

Inclusion Criteria

Exclusion Criteria

Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer

Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC

Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)